Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral MORF-057 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral MORF-057 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MORF 057 (Primary)
  • Indications Irritable bowel syndrome; Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Morphic Therapeutic

Most Recent Events

  • 25 Oct 2022 Data from this study strongly support the ongoing EMERALD-1 phase 2a study and the upcoming EMERALD-2 phase 2b study of MORF-057.
  • 25 Oct 2022 According to a Morphic Therapeutic media release, data from this study presented at the American College of Gastroenterology (ACG) Annual Meeting 2022.
  • 11 Oct 2022 Results (n=21) assessing safety, tolerability, and pharmacokinetics (PK) of MORF-057 presented at the 30th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top